End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.17 USD | +7.26% | +10.00% | -4.61% |
Business Summary
Number of employees: 9
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics for the Treatment of Non-alcoholic Steatohepatitis and Other Diseases
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Happel
CEO | Chief Executive Officer | 62 | 24/22/24 |
George Kemble
CHM | Chairman | 63 | 15/11/15 |
Elizabeth Rozek
CMP | Compliance Officer | 53 | 01/23/01 |
Chief Tech/Sci/R&D Officer | - | 01/13/01 | |
Chief Tech/Sci/R&D Officer | 61 | 01/21/01 | |
Merdad Parsey
BRD | Director/Board Member | 61 | 30/10/30 |
Gaeton Biscardi
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 01/07/01 |
Richard Rodgers
BRD | Director/Board Member | 57 | 01/15/01 |
Director/Board Member | 60 | 01/21/01 | |
David Happel
CEO | Chief Executive Officer | 62 | 24/22/24 |
Jinzi Wu
BRD | Director/Board Member | 61 | 01/19/01 |
George Kemble
CHM | Chairman | 63 | 15/11/15 |
Merdad Parsey
BRD | Director/Board Member | 61 | 30/10/30 |
- | - | ||
- | - | ||
- | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,520,490 | 0 | 0 | 81.64 % |
Stock B | 1 | 30,393,397 | 26,054,281 ( 85.72 %) | 0 |
Company contact information
Sagimet Biosciences, Inc.
155 Bovet Road Suite 303
94402, San Mateo
+650-561-8600
http://www.sagimet.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.61% | 175M | |
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- SGMT Stock
- Company Sagimet Biosciences Inc.